Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Gain Therapeutics, Inc. (GANX : NSDQ)

• Company Description    Gain Therapeutics Inc. is redefining drug discovery with its See-Tx(TM) target identification platform. It involved in identifying and optimizing allosteric binding sites which have never before been targeted. The company is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain Therapeutics Inc. is based in BETHESDA, Md. Number of Employees: 21

• Price / Volume Information    Yesterday's Closing Price: $1.78 Daily Weekly Monthly 20 Day Moving Average: 531,560 shares Shares Outstanding: 42.65 (millions) Market Capitalization: $75.92 (millions) Beta: 0.15 52 Week High: $4.34 52 Week Low: $1.41 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.82% -10.42% 12 Week -28.23% -33.65% Year To Date -44.72% -50.03%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4800 MONTGOMERY LANE SUITE 220 - BETHESDA,MD 20814 USA ph: 301-500-1556 fax: - ajammu@gaintherapeutics.com http://www.gaintherapeutics.com

• General Corporate Information    Officers Gene Mack - Chief Executive Officer and Director Khalid Islam - Chairman Gianluca Fuggetta - Senior Vice President Finance Dov Goldstein - Director Hans Peter Hasler - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 36269B105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 42.65 Most Recent Split Date: (:1) Beta: 0.15 Market Capitalization: $75.92 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.14 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.54 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.42 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 18.75% vs. Previous Quarter: -18.18% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -201.44 12/31/25 - -237.54 09/30/25 - -341.32 ROA 03/31/26 - -136.24 12/31/25 - -145.96 09/30/25 - -174.09 Current Ratio 03/31/26 - 4.69 12/31/25 - 6.63 09/30/25 - 2.52 Quick Ratio 03/31/26 - 4.69 12/31/25 - 6.63 09/30/25 - 2.52 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 0.33 12/31/25 - 0.48 09/30/25 - 0.16 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.02 12/31/25 - 0.02 09/30/25 - 0.05 Debt-to-Capital 03/31/26 - 1.91 12/31/25 - 1.59 09/30/25 - 4.82

Powered by Zacks Investment Research ©